Decreasing incidence of type 2 diabetes mellitus in the United States, 2007-2012: Epidemiologic findings from a large US claims database.
OBJECTIVE
To explore epidemiological trends in type 2 diabetes mellitus (T2D) in the US between 2007 and 2012 using a large US claims database, with a particular focus on demographics, prevalence, newly-diagnosed cases, and comorbidities.


METHODS
Truven Health MarketScan® Databases were used to identify patients with claims evidence of T2D in the years 2007 and 2012. Newly-diagnosed T2D was characterized by an absence of any T2D claims or related drug claims for 6months preceding the index claim. Demographic and comorbidity characteristics of the prevalent and new-onset T2D groups were compared and analyzed descriptively for trends over time.


RESULTS
The overall prevalence of T2D remained stable from 2007 (1.24 million cases/15.07 million enrolled; 8.2%) to 2012 (2.04 million cases/24.52 million enrolled; 8.3%), while the percentage of newly-diagnosed cases fell dramatically from 2007 (152,252 cases; 1.1%) to 2012 (147,011 cases; 0.65%). The mean age of patients with prevalent T2D was similar in 2007 (60.6y) and 2012 (60.0y), while the mean age of newly-diagnosed T2D patients decreased by 3years from 2007 (57.7y) to 2012 (54.8y). Hypertension and hyperlipidemia were the most common comorbidities, evident in 50-75% of T2D patients, and increased markedly from 2007 to 2012 in both prevalent and new-onset T2D populations. Cardiovascular disease decreased slightly in prevalent (-0.9%) and new-onset (-2.8%) cases.


CONCLUSIONS
This large US health claims database analysis suggests stabilization in prevalence and declining incidence of T2D over a recent 5-year period, a downward shift in age at T2D diagnosis, but increases in several comorbidities.
Novo Nordisk Inc., Plainsboro, NJ, USA. Electronic address: wayw@novonordisk.com.
Wayne
W
Weng
Novo Nordisk Inc., Plainsboro, NJ, USA.
Yuanjie
Y
Liang
Novo Nordisk Inc., Plainsboro, NJ, USA.
Edward S
ES
Kimball
Novo Nordisk Inc., Plainsboro, NJ, USA.
Todd
T
Hobbs
Novo Nordisk Inc., Plainsboro, NJ, USA.
Sheldon X
SX
Kong
Novo Nordisk Inc., Plainsboro, NJ, USA.
Brian
B
Sakurada
Novo Nordisk Inc., Plainsboro, NJ, USA.
Jonathan
J
Bouchard
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D015897:Comorbidity; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014481:United States / Q000453:epidemiology; D055815:Young Adult
Claims data; Comorbidity; Epidemiology; Incidence; Prevalence; Type 2 diabetes mellitus